Last reviewed · How we verify
TAA-AQ, Nasacort® AQ
Triamcinolone acetonide aqueous suspension is a corticosteroid that reduces inflammation and immune response in the nasal passages.
Triamcinolone acetonide aqueous suspension is a corticosteroid that reduces inflammation and immune response in the nasal passages. Used for Allergic rhinitis, Nasal symptoms associated with seasonal and perennial allergies.
At a glance
| Generic name | TAA-AQ, Nasacort® AQ |
|---|---|
| Sponsor | Sanofi |
| Drug class | Intranasal corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology / Allergy |
| Phase | FDA-approved |
Mechanism of action
TAA-AQ is an intranasal corticosteroid that binds to glucocorticoid receptors in nasal tissue, suppressing inflammatory cytokine production and reducing recruitment of inflammatory cells. This mechanism reduces nasal inflammation, congestion, and allergic symptoms by dampening the local immune response in the nasal mucosa.
Approved indications
- Allergic rhinitis
- Nasal symptoms associated with seasonal and perennial allergies
Common side effects
- Headache
- Pharyngitis
- Epistaxis
- Nasal irritation
- Cough
Key clinical trials
- Study of Triamcinolone Acetonide on the Growth Velocity of Children, Ages 3 to 9, With Perennial Allergic Rhinitis (PAR) (PHASE4)
- Nasacort AQ Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Children With Allergic Rhinitis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TAA-AQ, Nasacort® AQ CI brief — competitive landscape report
- TAA-AQ, Nasacort® AQ updates RSS · CI watch RSS
- Sanofi portfolio CI